Mariam Elmegaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariam Elmegaard has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Lars Køber
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
9 shared publications - Morten Schou
Department of Clinical Medicine, University of Copenhagen , Copenhagen
7 shared publications - Caroline Hartwell Garred
Department of Cardiology, Herlev and Gentofte University Hospital , Borgmester Ib Juuls Vej 1, 2730 Herlev
6 shared publications Morten Schou
Department of Cardiology Copenhagen University Hospital—Herlev and Gentofte Copenhagen Denmark
6 shared publications- Nina Nouhravesh
Department of Oncology, Rigshospitalet, Copenhagen University Hospital , Copenhagen
5 shared publications - Daniel Mølager Christensen
Department of Cardiology Copenhagen University Hospital—Herlev and Gentofte Copenhagen Denmark
4 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Chronic but not Transient Anemia Is Associated With Atrial Fibrillation Recurrence After Catheter Ablation
Background: Anemia is common in patients with atrial fibrillation (AF). Prior studies have associated anemia—based on a single pre‐procedural hemoglobin measurement—with AF recurrence after catheter ablation. However, it remains unclear whether chronic anemia confers a different risk compared with transient anemia. This study evaluated the association between transient and chronic anemia and AF recurrence following first‐time catheter ablation. Methods: In this nationwide cohort study, we included 15 017 patients from the Danish National Ablation Database undergoing first‐time AF ablation between 2010 and 2024 with available hemoglobin measurements within 12 months prior to the procedure. Patients were categorized as having no anemia, transient anemia, or chronic anemia based on repeated hemoglobin measurements. The primary outcome was AF recurrence within 1 year after a 90‐day blanking period, defined as a composite of AF‐related hospitalization, cardioversion, antiarrhythmic drug use, or repeat ablation. Associations were assessed using multivariable Cox proportional hazards models. Results: A total of 877 patients (5.8%) had chronic anemia and 1592 (10.6%) had transient anemia. During follow‐up, 3445 patients (23.6%) experienced AF recurrence. The 1‐year cumulative incidence of recurrence was highest in patients with chronic anemia (32.5%), followed by transient anemia (24.2%) and no anemia (23.0%). Compared with non‐anemic patients, chronic anemia was independently associated with an increased risk of AF recurrence (adjusted hazard ratio [HR]: 1.36; 95% confidence interval [CI]: 1.18–1.56), whereas transient anemia was not (HR: 0.98; 95% CI: 0.87–1.10). Conclusion: Chronic—but not transient—anemia prior to first‐time catheter ablation was independently associated with a higher risk of AF recurrence.
- 12 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Open AccessChronic but not Transient Anemia Is Associated With Atrial Fibrillation Recurrence After Catheter Ablation
Background: Anemia is common in patients with atrial fibrillation (AF). Prior studies have associated anemia—based on a single pre‐procedural hemoglobin measurement—with AF recurrence after catheter ablation. However, it remains unclear whether chronic anemia confers a different risk compared with transient anemia. This study evaluated the association between transient and chronic anemia and AF recurrence following first‐time catheter ablation. Methods: In this nationwide cohort study, we included 15 017 patients from the Danish National Ablation Database undergoing first‐time AF ablation between 2010 and 2024 with available hemoglobin measurements within 12 months prior to the procedure. Patients were categorized as having no anemia, transient anemia, or chronic anemia based on repeated hemoglobin measurements. The primary outcome was AF recurrence within 1 year after a 90‐day blanking period, defined as a composite of AF‐related hospitalization, cardioversion, antiarrhythmic drug use, or repeat ablation. Associations were assessed using multivariable Cox proportional hazards models. Results: A total of 877 patients (5.8%) had chronic anemia and 1592 (10.6%) had transient anemia. During follow‐up, 3445 patients (23.6%) experienced AF recurrence. The 1‐year cumulative incidence of recurrence was highest in patients with chronic anemia (32.5%), followed by transient anemia (24.2%) and no anemia (23.0%). Compared with non‐anemic patients, chronic anemia was independently associated with an increased risk of AF recurrence (adjusted hazard ratio [HR]: 1.36; 95% confidence interval [CI]: 1.18–1.56), whereas transient anemia was not (HR: 0.98; 95% CI: 0.87–1.10). Conclusion: Chronic—but not transient—anemia prior to first‐time catheter ablation was independently associated with a higher risk of AF recurrence.
- 11 June 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (10) , 103176
A Randomized Clinical Implementation Trial Testing a Digital Strategy to Increase SGLT2 Inhibitor Initiation in Heart Failure
- 11 June 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (10) , 103176
A Randomized Clinical Implementation Trial Testing a Digital Strategy to Increase SGLT2 Inhibitor Initiation in Heart Failure
- 27 April 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Modification of the association between age and mortality in heart failure by frailty status
Aims: Heart failure (HF) disproportionately affects older patients, yet evidence guiding management in the oldest and frailest patients remains limited. We evaluated the influence of age and frailty on mortality and use of guideline-directed medical therapy (GDMT). Methods: Using nationwide Danish registry data, we identified all patients with new-onset HF (2013–22), stratified by age (<65, 65–79, ≥80 years) and frailty status according to the Hospital Frailty Risk Score (low, intermediate, high). We assessed all-cause and cardiovascular mortality 2 years after HF diagnosis and evaluated GDMT use across age and frailty groups using logistic regression. Results: Among 79 193 patients with HF, 24% were aged <65 years, 41% 65–79, and 35% ≥80. Frailty significantly modified the association between age and mortality (interaction P < .001). Patients with high frailty reached comparable 2-year mortality risks at younger ages than patients with lower frailty. The following had similar 2-year mortality: low-frailty patients aged 80 years (22.1%, 95% confidence interval, 21.4–22.8), intermediate-frailty patients aged 70 years (22.8%, 21.9–23.8), and high-frailty patients aged 47 (22.8%, 18.0–28.4). Similar results were seen for cardiovascular mortality. Guideline-directed medical therapy use was lower in high frailty than low-frailty patients across all age groups. Moreover, within each frailty group, patients aged ≥80 years had lower odds of receiving GDMT compared with those aged <65 (reference). Conclusion: Frailty alters mortality risk in HF beyond chronological age, resulting in prognostic heterogeneity regardless of age. Our findings support the need for both frailty-informed and age-based management strategies in HF across all ages.
- 27 April 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Modification of the association between age and mortality in heart failure by frailty status
Aims: Heart failure (HF) disproportionately affects older patients, yet evidence guiding management in the oldest and frailest patients remains limited. We evaluated the influence of age and frailty on mortality and use of guideline-directed medical therapy (GDMT). Methods: Using nationwide Danish registry data, we identified all patients with new-onset HF (2013–22), stratified by age (<65, 65–79, ≥80 years) and frailty status according to the Hospital Frailty Risk Score (low, intermediate, high). We assessed all-cause and cardiovascular mortality 2 years after HF diagnosis and evaluated GDMT use across age and frailty groups using logistic regression. Results: Among 79 193 patients with HF, 24% were aged <65 years, 41% 65–79, and 35% ≥80. Frailty significantly modified the association between age and mortality (interaction P < .001). Patients with high frailty reached comparable 2-year mortality risks at younger ages than patients with lower frailty. The following had similar 2-year mortality: low-frailty patients aged 80 years (22.1%, 95% confidence interval, 21.4–22.8), intermediate-frailty patients aged 70 years (22.8%, 21.9–23.8), and high-frailty patients aged 47 (22.8%, 18.0–28.4). Similar results were seen for cardiovascular mortality. Guideline-directed medical therapy use was lower in high frailty than low-frailty patients across all age groups. Moreover, within each frailty group, patients aged ≥80 years had lower odds of receiving GDMT compared with those aged <65 (reference). Conclusion: Frailty alters mortality risk in HF beyond chronological age, resulting in prognostic heterogeneity regardless of age. Our findings support the need for both frailty-informed and age-based management strategies in HF across all ages.
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e044072
Care and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022
Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e044072
Open AccessCare and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022
Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.
- Open Access
- 23 January 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e81949
Inequity in Access to and Use of Digital Health Technologies in Routine Heart Failure Care: Protocol for a Scoping Review
Background: Heart failure (HF) is a global health challenge characterized by high mortality, morbidity, and economic burden. The development of digital health technologies offers promising tools for prevention, early detection, and management of HF, potentially improving prognoses and reducing costs. However, these innovations may also widen existing health disparities related to socioeconomic status, geography, and race/ethnicity. Objective: This scoping review will examine and map existing evidence on socioeconomic, geographic, and racial/ethnic differences in access to and use of digital health technologies for HF care in routine practice. Methods: The writing of this protocol followed the methodological framework by Arksey and O’Malley, including (1) identifying the research question; (2) identifying relevant studies; (3) selecting studies to be included in the review; (4) charting the data; and (5) collating, summarizing, and reporting the results. Eligible studies must examine digital health technologies in adults (aged ≥18 years) with any type of HF and report on social determinants of health, geography, or race/ethnicity. Observational study designs will be included. Searches will be conducted in Embase, PubMed, Google Scholar, and Scopus. A 2-stage screening process will determine study eligibility, and data will be extracted using a standardized form. Results: The project is funded. Data collection is expected to begin by the beginning of 2026. Conclusions: This scoping review will map existing evidence on differences in access to and use of digital health technologies for HF care. The findings are anticipated to highlight patterns and gaps in the literature, informing future research and strategies for equitable implementation.
- 23 January 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e81949
Open AccessInequity in Access to and Use of Digital Health Technologies in Routine Heart Failure Care: Protocol for a Scoping Review
Background: Heart failure (HF) is a global health challenge characterized by high mortality, morbidity, and economic burden. The development of digital health technologies offers promising tools for prevention, early detection, and management of HF, potentially improving prognoses and reducing costs. However, these innovations may also widen existing health disparities related to socioeconomic status, geography, and race/ethnicity. Objective: This scoping review will examine and map existing evidence on socioeconomic, geographic, and racial/ethnic differences in access to and use of digital health technologies for HF care in routine practice. Methods: The writing of this protocol followed the methodological framework by Arksey and O’Malley, including (1) identifying the research question; (2) identifying relevant studies; (3) selecting studies to be included in the review; (4) charting the data; and (5) collating, summarizing, and reporting the results. Eligible studies must examine digital health technologies in adults (aged ≥18 years) with any type of HF and report on social determinants of health, geography, or race/ethnicity. Observational study designs will be included. Searches will be conducted in Embase, PubMed, Google Scholar, and Scopus. A 2-stage screening process will determine study eligibility, and data will be extracted using a standardized form. Results: The project is funded. Data collection is expected to begin by the beginning of 2026. Conclusions: This scoping review will map existing evidence on differences in access to and use of digital health technologies for HF care. The findings are anticipated to highlight patterns and gaps in the literature, informing future research and strategies for equitable implementation.
- 18 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (27) , 3625-3635
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.
- 18 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (27) , 3625-3635
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.
- Open Access
- 13 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study
- 13 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Open AccessCare and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study
- Open Access
- 19 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (6) , e032539
Temporal Trends in the Initiation of Dialysis Among Patients With Heart Failure With or Without Diabetes: A Nationwide Study From 2002 to 2016
Background: The incidence and distribution of acute and chronic dialysis among patients with heart failure (HF), stratified by diabetes, remain uncertain. We hypothesized that with improved survival and rising comorbidities, the demand for dialysis would increase over time. Methods and Results: Patients with incident HF, aged 18 to 100 years, between 2002 and 2016, were identified using Danish nationwide registers. Primary outcomes included acute and chronic dialysis initiation, HF‐related hospitalization, and all‐cause mortality. These outcomes were assessed in 2002 to 2006, 2007 to 2011, and 2012 to 2016, stratified by diabetes. We calculated incidence rates (IRs) per 1000 person‐years and hazard ratios (HR) using multivariable Cox regression. Of 115 533 patients with HF, 2734 patients received acute dialysis and 1193 patients received chronic dialysis. The IR was 8.0 per 1000 and 3.5 per 1000 person‐years for acute and chronic dialysis, respectively. Acute dialysis rates increased significantly among patients with diabetes over time, while no significant changes occurred in those without diabetes, chronic dialysis, HF‐related hospitalization, or overall mortality. Diabetes was associated with significantly higher HRs of acute and chronic dialysis, respectively, compared with patients without diabetes (HR, 2.07 [95% CI, 1.80–2.39] and 2.93 [95% CI, 2.40–3.58] in 2002 to 2006; HR, 2.45 [95% CI, 2.14–2.80] and 2.86 [95% CI, 2.32–3.52] in 2007 to 2011; and 2.69 [95% CI, 2.33–3.10] and 3.30 [95% CI, 2.69–4.06] in 2012 to 2016). Conclusions: The IR of acute and chronic dialysis remained low compared with HF‐related hospitalizations and mortality. Acute dialysis rates increased significantly over time, contrasting no significant trends in other outcomes. Diabetes exhibited over 2‐fold increased rates of the outcomes. These findings emphasize the importance of continued monitoring and renal care in patients with HF, especially with diabetes, to optimize outcomes and prevent adverse events.
- 19 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (6) , e032539
Open AccessTemporal Trends in the Initiation of Dialysis Among Patients With Heart Failure With or Without Diabetes: A Nationwide Study From 2002 to 2016
Background: The incidence and distribution of acute and chronic dialysis among patients with heart failure (HF), stratified by diabetes, remain uncertain. We hypothesized that with improved survival and rising comorbidities, the demand for dialysis would increase over time. Methods and Results: Patients with incident HF, aged 18 to 100 years, between 2002 and 2016, were identified using Danish nationwide registers. Primary outcomes included acute and chronic dialysis initiation, HF‐related hospitalization, and all‐cause mortality. These outcomes were assessed in 2002 to 2006, 2007 to 2011, and 2012 to 2016, stratified by diabetes. We calculated incidence rates (IRs) per 1000 person‐years and hazard ratios (HR) using multivariable Cox regression. Of 115 533 patients with HF, 2734 patients received acute dialysis and 1193 patients received chronic dialysis. The IR was 8.0 per 1000 and 3.5 per 1000 person‐years for acute and chronic dialysis, respectively. Acute dialysis rates increased significantly among patients with diabetes over time, while no significant changes occurred in those without diabetes, chronic dialysis, HF‐related hospitalization, or overall mortality. Diabetes was associated with significantly higher HRs of acute and chronic dialysis, respectively, compared with patients without diabetes (HR, 2.07 [95% CI, 1.80–2.39] and 2.93 [95% CI, 2.40–3.58] in 2002 to 2006; HR, 2.45 [95% CI, 2.14–2.80] and 2.86 [95% CI, 2.32–3.52] in 2007 to 2011; and 2.69 [95% CI, 2.33–3.10] and 3.30 [95% CI, 2.69–4.06] in 2012 to 2016). Conclusions: The IR of acute and chronic dialysis remained low compared with HF‐related hospitalizations and mortality. Acute dialysis rates increased significantly over time, contrasting no significant trends in other outcomes. Diabetes exhibited over 2‐fold increased rates of the outcomes. These findings emphasize the importance of continued monitoring and renal care in patients with HF, especially with diabetes, to optimize outcomes and prevent adverse events.